BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29577257)

  • 21. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores.
    Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Romiti GF; Marin F; Lip GYH
    J Am Heart Assoc; 2018 Sep; 7(18):e009766. PubMed ID: 30371183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy.
    Roldán V; Marín F; Fernández H; Manzano-Fernandez S; Gallego P; Valdés M; Vicente V; Lip GYH
    Chest; 2013 Jan; 143(1):179-184. PubMed ID: 22722228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    Am J Med; 2018 May; 131(5):574.e13-574.e27. PubMed ID: 29274754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.
    Shukla A; Jain A; Kahalekar V; Bendkhale S; Gogtay N; Thatte U; Bhatia S
    Hepatol Int; 2019 Mar; 13(2):214-221. PubMed ID: 30617764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
    Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
    Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
    Am Heart J; 2018 Mar; 197():27-34. PubMed ID: 29447781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.
    Senoo K; Lip GY
    Int J Cardiol; 2016 Oct; 221():379-82. PubMed ID: 27409565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.
    Misasi S; Martini G; Paoletti O; Calza S; Scovoli G; Marengoni A; Testa S; Caimi L; Marchina E
    Medicine (Baltimore); 2016 Dec; 95(52):e5451. PubMed ID: 28033245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project.
    Lip GY; Banerjee A; Lagrenade I; Lane DA; Taillandier S; Fauchier L
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):941-8. PubMed ID: 22923275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study.
    Chao TF; Lip GYH; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Chen SA
    Int J Cardiol; 2018 Mar; 254():157-161. PubMed ID: 29407081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
    Sehgal T; Hira JK; Ahluwalia J; Das R; Vijayvergiya R; Rana SS; Varma N
    Drug Discov Ther; 2015 Dec; 9(6):404-10. PubMed ID: 26781925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study.
    Sridharan K; Modi T; Bendkhale S; Kulkarni D; Gogtay NJ; Thatte UM
    Curr Clin Pharmacol; 2016; 11(1):62-8. PubMed ID: 26777610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.
    Lip GYH; Lane DA; Buller H; Apostolakis S
    Chest; 2013 Dec; 144(6):1839-1847. PubMed ID: 24009027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
    Jiménez-Varo E; Cañadas-Garre M; Gutiérrez-Pimentel MJ; Calleja-Hernández MA
    Pharmacogenet Genomics; 2014 Oct; 24(10):501-13. PubMed ID: 25089947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores.
    Proietti M; Senoo K; Lane DA; Lip GY
    Sci Rep; 2016 Apr; 6():24376. PubMed ID: 27067661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
    Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
    Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
    Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
    Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications.
    Sychev DV; Ignatyev IV; Emelyanov NV; Milovanova VV; Kossovskaya AV; Kukes IV; Tashenova AI; Kukes VG
    Bull Exp Biol Med; 2012 Oct; 153(6):886-8. PubMed ID: 23113310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.